BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...
LifeVantage (NASDAQ:LFVN – Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, January 28th. Analysts expect the company to announce earnings of $0.14 ...